+

WO1999002707A1 - Proteines de fusion comprenant des structures bispiralees - Google Patents

Proteines de fusion comprenant des structures bispiralees Download PDF

Info

Publication number
WO1999002707A1
WO1999002707A1 PCT/GB1998/002040 GB9802040W WO9902707A1 WO 1999002707 A1 WO1999002707 A1 WO 1999002707A1 GB 9802040 W GB9802040 W GB 9802040W WO 9902707 A1 WO9902707 A1 WO 9902707A1
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
region
protein
fusion
cells
Prior art date
Application number
PCT/GB1998/002040
Other languages
English (en)
Inventor
John Walker
Bruno Miroux
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to EP98933782A priority Critical patent/EP1012310A1/fr
Priority to CA002290716A priority patent/CA2290716A1/fr
Priority to AU83481/98A priority patent/AU740755B2/en
Priority to JP2000502201A priority patent/JP2001509390A/ja
Publication of WO1999002707A1 publication Critical patent/WO1999002707A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Definitions

  • the present invention relates to novel fusion partners for recombinantly-produced proteins.
  • the invention relates to a polypeptide having a coiled coil structure which is resistant to proteolytic degradation and capable of. acting as a carrier to increase the immunogenicity of a protein fused to it.
  • Proteins are produced in a wide variety of expression systems which are based on, for example, bacterial, yeast, insect, plant and mammalian cells, one of the problems associated with the production of proteins by recombinant means is that host cells contain enzymes which degrade proteins and the presence of such enzymes present particular difficulties in the production of small polypeptides.
  • DNA encoding the protein of interest is fused in-frame to a fusion partner protein and the resulting fusion is expressed.
  • a linker sequence encoding a protease cleavage sited between the two parts of the fusion is included to allow cleavage of the fusion after it has been recovered from its host cell.
  • the fusion partner protein is often one which may be recovered and purified by some form of highly specific affinity purification means.
  • affinity purification means include, for example, glutathione-S-transferase, maltose binding protein and ⁇ - lactamase.
  • fusion partner proteins are all relatively large and thus have a number of disadvantages. For example, it is essential to remove them before any meaningful procedure may be carried out on the protein of interest, since they are too large to enable it to function with any degree of independence. Many small polypeptides are still thus made by chemical synthesis.
  • the present invention arose in the course of our investigations into the structure of a bovine ATPase inhibitor protein, IF,.
  • IF bovine ATPase inhibitor protein
  • This is a small - 84 amino acid - protein which helps to regulate the activity of ATP synthase in mitochondria.
  • Our analysis of this protein revealed that the C-terminal region of the protein (amino acids 48 to 84) forms a coiled-coil structure.
  • Coiled-coils are formed by two or three alpha-helices in parallel and in register and display a pattern of hydrophilic and hydrophobic residues that is repeated every seven residues (Lupas et al. , Science 252; 1162-1164, 1991).
  • the right-handed alpha-helices are wrapped around each other with a slightly left-handed superhelical twist.
  • Coiled-coils are well known in fibrous proteins such as keratin, myosin and tropomyosin, but are also found in other proteins such as those which contain a leucine zipper motif.
  • Coiled-coil regions of proteins generally comprise a heptad repeat, with the amino acids of each repeat being designated a to g.
  • Amino acids a and d of each repeat are generally hydrophobic amino acids.
  • fusion proteins which comprise the coiled-coil region of bovine IF, ATPase inhibitor protein and a short sequence of a second protein.
  • these fusion proteins can be expressed at high levels and isolated in intact form, from which the second protein may efficiently be recovered.
  • the use of coiled-coils as a fusion partner protein in a recombinant expression system thus allows expression of a desired polypeptide in a manner which protects the polypeptide from degradation in the host cell.
  • fusion protein comprising:
  • the first region may be located either N-terminal to or C-terminal to the second region. However it is preferred that it is located N-terminal to the second region, and most preferably it is at the N-terminus of the fusion protein.
  • the fusion protein further comprises a cleavable linker region between the first and second regions.
  • the invention further comprises a nucleic acid encoding the fusion protein of the invention, and preferably the nucleic acid forms part of an expression vector comprising the nucleic acid operably linked to a promoter.
  • the invention further comprises a host cell carrying the expression vector of the invention, and a method of preparing the fusion protein of the invention comprising (i) culturing the host cell under conditions which provide for the expression of the fusion protein from the expression vector within the host cell; and (ii) recovering the fusion protein from the cell.
  • the method optionally further comprises cleaving the protein at the protease cleavable linker and recovering the second region.
  • Figure 1 Expression plasmids encoding the truncated IF, inhibitor fused to various fragments of the uncl and uncll genes expressed in E. coli C41(DE3) cells and the product separated on a coomassie stained SDS-PAGE gel. Lanes as follows: 1 : IF,; 2: IF r al; 3: IF,-a3: 4: IF,-I1; 5: IF1-I2. Molecular weight markers are on the left; a is subunit a of the E. coli F ⁇ F 0 ATP synthase; I is subunit I of the E. coli F,F 0 ATP synthase. See Table 1 for complete nomenclature.
  • Figure 2 Expression of peptides ranging from 2 to 54 amino acids in length as fusions with IF, (44-84), separated on SDS-PAGE. See description for details.
  • Figure 3 Purification of fusion proteins on reverse phase HPLC.
  • a and C chromatogram of the purification of IF r al and IF r a3 respectively.
  • B and D SDS-PAGE analysis of the purification of IF r al and IF r a3 respectively.
  • IB inclusion bodies; numbers indicate the collected fractions.
  • Figure 4 Purification of fusion proteins on reverse phase HPLC.
  • a and C chromatogram of the purification of IF r Il and IF r I2 respectively.
  • B and D SDS-PAGE analysis of the purification of IF r Il and IF,-I2 respectively.
  • IB inclusion bodies; numbers indicate the collected fractions.
  • Figure 5 Purification of fusion proteins according to the invention by other methods. II: from inclusion bodies: If-al is expressed as inclusion bodies and solubilised using 6M Guanidinium chloride and purified by reverse phase HPLC as for Figure 3. If-UCP270 fusion protein is solubilised in the presence of urea and purified on a nickel column in the presence of LDAO detergent (see text for details). 21: the three fusion proteins If- UCP1P1, If-UCP2P2 and If-UCP3P3 are soluble in the bacterial cytoplasm and are purifiedby anion exchange chromatography on S-Sepharose followed by affinity chromatography on a nickel column. All protein samples are analysed by SDS-PAGE after purification. The gels are stained with coomassie blue dye 83. Detailed Description of the Invention.
  • the first region of the fusion protein of the invention may comprise any natural or synthetic coiled-coil polypeptide.
  • Such regions are found in a variety of proteins, including keratin, myosin, tropomyosin or laminin, or proteins such as those which contain a leucine zipper motif such as GCN4 or haemagglutinin, or other proteins such as IF, ATPase inhibitor protein, which is preferably mammalian IF, ATPase inhibitor protein.
  • IF ATPase inhibitor protein
  • the sequence of the rat and bovine proteins are illustrated in the accompanying examples.
  • Other mammalian IF, ATPase inhibitor proteins such as human or murine IF, ATPase inhibitor protein may be used.
  • synthetic variants of such proteins or regions thereof may be used provided that they retain the ability to form coiled-coils. Because the regions of coiled-coil proteins which form coiled-coils have a heptad repeat structure, synthetic variants will generally differ from the naturally-occurring proteins by substitution, particularly conservative substitutions, or by insertion of one or more complete heptad repeats.
  • the insertion will be such as to maintain the a-g residue structure mentioned above.
  • the insertion will be of one or more complete a- g repeats between the g and a of successive repeats of the naturally-occurring protein.
  • insertions may also be made between other residues of the heptad repeat so long as the insertion maintains the heptad structure.
  • Synthetic variants of naturally-occurring coiled-coil proteins may be made by standard recombinant " DNA techniques. For example, site-directed mutagenesis may be used to introduce changes to the coding region of a DNA encoding a naturally-occurring coiled-coil protein. Where insertions are to be made, synthetic DNA encoding the insertion together with 5' and 3' flanking regions corresponding to the naturally -occurring sequence either side of the insertion site. The flanking regions will contain convenient restriction sites corresponding to sites in the naturally-occurring sequence so that the sequence may be cut with the appropriate enzyme(s) and the synthetic DNA ligated into the cut. The DNA is then expressed in accordance with the invention to make the encoded protein. These methods are only illustrative of the numerous standard techniques known in the art for manipulation of DNA sequences and other known techniques may also be used.
  • a fusion protein according to the invention will comprise as many heptad repeats as required to form a coiled coil structure. Generally, this will be three or more, (the fewer the better in order to minimize the contribution to the fusion protein of the coiled-coil forming sequence). This can be especially important where in structural determination of proteins by NMR it is often necessary to carry out isotopic labelling with 15 N or lj C. This is expensive and with a long fusion partner much of the incorporated radioactivity is removed if the carrier protein (e.g. GST in many cases) is cleaved off. Thus the fusion partner will be between about 25 and about 100 amino acids in size, comprising from 3 to
  • heptad repeat units capable of forming a coiled-coil structure.
  • any putative coiled-coil region may be examined by the algorithms of Lupas et al. or Berger et al.
  • the sequences may also be synthesised by recombinant DNA techniques and solutions of the sequence examined for circular dichroism spectra at different concentrations. Where coiled-coil formation occurs (as opposed to non-specific aggregation) the spectra will remain constant at a range of dilutions (whereas non-specific aggregation will be diluted out).
  • the first region may also comprise sequences flanking the heptad repeats. These may be necessary to maintain the overall structure of the first region so that the alpha-helical coil structure of the heptad repeats may be formed.
  • the four heptad repeat units of the bovine IF, ATPase inhibitor are found at residues 53 to 80.
  • residues 44 to 84 of this protein is a preferred embodiment of the invention.
  • suitable regions of this protein - or corresponding portions of mammalian homologues - may be used, for example from 1 to 84, e.g. from 23 to 84, or from 1 to 78, e.g. from 44 to 78.
  • non coiled-coil forming amino acids may be present at either or both of the N- and/or C-terminals of the first region.
  • These sequences may be from the protein from which the coiled-coil regions are derived or from any other natural or synthetic source. In principle the region is unimportant provided that it dose not affect the formation of coiled-coil structures.
  • the second region of the fusion protein according to the invention may comprise any polypeptide sequence of interest which is not naturally associated with the first region. Usually this will mean that the sequence of interest will be found in nature encoded by a gene different from the gene encoding the first region. This may be determined easily by examining the sequences of the first and second regions against publicly available sequence databanks.
  • the second region may be from the same species as the first region, or from a different species. It is also possible that the first and second regions are derived from portions of the same protein but are present in the fusion protein of the invention in a manner different from the natural protein sequence.
  • the fusion protein according to the invention may be of any size although in general the invention is particularly useful when the polypeptide sequence of interest is short, e.g. from 2 to 100 amino acids in length, preferably 2 to 50 or even 2 to 30 or 5 to 10 amino acids in size. However larger polypeptide sequences of interest, e.g. up 150, 200, 400 or 1000 amino acids are also contemplated.
  • the invention is particularly advantageous for the preparation of small polypeptides which are currently difficult to manufacture by recombinant means.
  • polypeptides examples include fragments of chaperone proteins, metabolic enzymes, DNA and RNA binding proteins, antibodies, viral proteins, intrinsic membrane proteins (including transport proteins from mitochondria, seven-helix receptor molecules, T-cell receptors), and cytoskeletal complexes, antibody binding peptides, peptide hormones (and other biologically active peptides made by ribosomal synthesis), and small subunits from multi-subunit biological structures such as respiratory enzymes, the ATP synthase.
  • the invention is suitable for use with peptides of any dimension, but the advantageous properties thereof are best exploited with small polypeptides. for example from 2 to 50 amino acids in length, particularly from 2 to 20 amino acids in length, and preferably from 5 to 10 amino acids in length.
  • a particular advantage of the present invention is that peptides may be produced by recombinant DNA technology which are so short that they would previously have been made by oligopeptide synthesis techniques.
  • libraries of peptides for example of mutants of biologically active peptides, which may be screened or otherwise analysed, cheaply and efficiently in recombinant expression systems, particularly bacterial expression systems.
  • the cleavable linker region is a protease cleavable linker, although other linkers, cleavable for example by small molecules, may be used. These include Met-X sites, cleavable by cyanogen bromide, Asn-Gly, cleavable by hydroxy lamine, Asp-Pro, cleavable by weak acid and Trp-X celavable by, inter alia, NBS- skatole.
  • Protease cleavage sites are preferred due to the milder cleavage conditions necessary and are found in, for example, factor Xa, thrombin and collagenase. Any of these may be used. The precise sequences are available in the art and the skilled person will have no difficulty in selecting a suitable cleavage site.
  • the protease cleavage region targeted by Factor Xa is I E G R.
  • the protease cleavage region targeted by Enterokinase is D D D D D K.
  • the protease cleavage region targeted by Thrombin is L V P R G.
  • the invention also provides nucleic acid encoding the fusion proteins of the invention. These may be constructed using standard recombinant DNA methodologies.
  • the nucleic acid may be RNA or DNA and is preferably DNA. Where it is RNA, manipulations may be performed via cDNA intermediates.
  • a nucleic acid sequence encoding the first region will be prepared and suitable restriction sites provided at the 5' and/or 3' ends. Conveniently the sequence is manipulated in a standard laboratory vector, such as a plasmid vector based on pBR322 or pUC19 (see below). Reference may be made to
  • Nucleic acid encoding the second region may likewise be provided in a similar vector system. Sources of nucleic acid may be ascertained by reference to published literature or databanks such as Genbank.
  • Nucleic acid encoding the desired first or second region may be obtained from academic or commercial sources where such sources are willing to provide the material or by synthesising or cloning the appropriate sequence where only the sequence data are available. Generally this may be done by reference to literature sources which describe the cloning of the gene in question.
  • nucleic acid sequences known in the art can be characterised as those nucleotide sequences which hybridise to the nucleic acid sequences known in the art.
  • Stringency of hybridisation refers to conditions under which polynucleic acids hybrids are stable. Such conditions are evident to those of ordinary skill in the field. As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature (Tm) of the hybrid which decreases approximately 1 to 1.5 °C with every 1 % decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridisation reaction is performed under conditions of higher stringency, followed by washes of varying stringency.
  • high stringency refers to conditions that permit hybridisation of only those nucleic acid sequences that form stable hybrids in 1 M Na+ at 65-68 °C.
  • High stringency conditions can be provided, for example, by hybridisation in an aqueous solution containing 6x SSC. 5x Denhardt's, 1 % SDS (sodium dodecyl sulphate), 0.1 Na+ pyrophosphate and 0.1 mg/ml denatured salmon sperm DNA as non specific competitor.
  • high stringency washing may be done in several steps, with a final wash (about 30 min) at the hybridisation temperature in 0.2 - O. lx SSC, 0.1 % SDS.
  • Moderate stringency refers to conditions equivalent to hybridisation in the above described solution but at about 60-62 °C. In that case the final wash is performed at the hybridisation temperature in lx SSC, 0.1 % SDS.
  • Low stringency refers to conditions equivalent to hybridisation in the above described solution at about 50-52 °C. In that case, the final wash is performed at the hybridisation temperature in 2x SSC, 0.1 % SDS.
  • nucleic acids suitable for forming the first or second region of a fusion protein according to the invention are obtainable according to methods well known in the art.
  • a DNA of the invention is obtainable by chemical synthesis, using polymerase chain reaction (PCR) or by screening a genomic library or a suitable cDNA library prepared from a source believed to possess the desired nucleic acid and to express it at a detectable level.
  • PCR polymerase chain reaction
  • Chemical methods for synthesis of a nucleic acid of interest include triester, phosphite, phosphoramidite and H-phosphonate methods. PCR and other autoprimer methods as well as oligonucleotide synthesis on solid supports. These methods may be used if the entire nucleic acid sequence of the nucleic acid is known, or the sequence of the nucleic acid complementary to the coding strand is available.
  • the target amino acid sequence is known, one may infer potential nucleic acid sequences using known and preferred coding residues for each amino acid residue.
  • cDNA expression libraries are screened with probes or analytical tools designed to identify the gene of interest or the protein encoded by it.
  • suitable means include monoclonal or polyclonal antibodies that recognise and specifically bind to the desired protein; oligonucleotides of about 20 to 80 bases in length that encode known or suspected cDNA encoding the desired protein from the same or different species; and/or complementary or homologous cDNAs or fragments thereof that encode the same or a hybridising gene.
  • Appropriate probes for screening genomic DNA libraries include, but are not limited to oligonucleotides, cDNAs or fragments thereof that encode the same or hybridising DNA; and/or homologous genomic DNAs or fragments thereof.
  • a nucleic acid encoding the desired protein may be isolated by screening suitable cDNA or genomic libraries under suitable hybridisation conditions with a probe.
  • a probe is e.g. a single-stranded DNA or RNA that has a sequence of nucleotides that includes between 10 and 50, preferably between 15 and 30 and most preferably at least about 20 contiguous bases that are the same as (or the complement of) an equivalent or greater number of contiguous bases from a known or desired sequence.
  • the nucleic acid sequences selected as probes should be of sufficient length and sufficiently unambiguous so that false positive results are minimised.
  • the nucleotide sequences are usually based on conserved or highly homologous nucleotide sequences or regions of the desired protein.
  • the nucleic acids used as probes may be degenerate at one or more positions. The use of degenerate oligonucleotides may be of particular importance where a library is screened from a species in which preferential codon usage in that species is not known.
  • Preferred regions from which to construct probes include 5' and/or 3 ' coding sequences, sequences predicted to encode ligand binding sites, and the like.
  • nucleic acid probes of the invention are labelled with suitable label means for ready detection upon hybridisation.
  • a suitable label means is a radiolabel.
  • the preferred method of labelling a DNA fragment is by incorporating ⁇ 32 P dATP with the Klenow fragment of DNA polymerase in a random priming reaction, as is well known in the art.
  • Oligonucleotides are usually end-labelled with ⁇ 32 P-labelled ATP and polynucleotide kinase.
  • other methods e.g. non-radioactive
  • positive clones are identified by detecting a hybridisation signal; the identified clones are characterised by restriction enzyme mapping and/or DNA sequence analysis, and then examined to ascertain whether they include DNA encoding a complete polypeptide (i.e., if they include translation initiation and termination codons). If the selected clones are incomplete, they may be used to rescreen the same or a different library to obtain overlapping clones. If the library is genomic, then the overlapping clones may include exons and introns. If the library is a cDNA library, then the overlapping clones will include an open reading frame. In both instances, complete clones may be identified by comparison with the DNAs and deduced amino acid sequences provided herein.
  • nucleic acid of the invention can be readily modified by nucleotide substitution, nucleotide deletion, nucleotide insertion or inversion of a nucleotide stretch, and any combination thereof.
  • Such mutants can be used e.g. to produce a mutant that has an amino acid sequence differing from the sequences as found in nature. Mutagenesis may be predetermined (site-specific) or random. A mutation which is not a silent mutation must not place sequences out of reading frames and preferably will not create complementary regions that could hybridise to produce secondary mRNA structure such as loops or hairpins.
  • sequence of the IF, polypeptide coiled coil provided herein as SEQ. ID. No. 1. or suitable fragments thereof as discussed above, may be used as a probe for the identification of further suitable sequences.
  • the first or second region may also be manipulated to introduce an appropriate restriction enzyme site at the terminus which is to be linked to the nucleic acid encoding the first region via a corresponding restriction enzyme site. Desirably the sites will be either the same or at least have matching cohesive ends.
  • the first and second regions may be joined by alternative means; for example, first region may be incorporated into primers used to isolate or replicate the second region.
  • protease cleavable linker region is required, this maybe introduced into the linked first and second regions (e.g. into the restriction site linking the two) or introduced into one or the other prior to their combination.
  • vector refers to discrete elements that are used to introduce heterologous DNA into cells for either expression or replication thereof. Selection and use of such vehicles are well within the skill of the artisan. Many vectors are available, and selection of appropriate vector will depend on the intended use of the vector, i.e. whether it is to be used for DNA amplification or for DNA expression, the size of the DNA to be inserted into the vector, and the host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of
  • the vector components generally include, but are not limited to, one or more of the following: an origin of replication, one or more marker genes, an enhancer element, a promoter, a transcription termination sequence and a signal sequence.
  • Both expression and cloning vectors generally contain nucleic acid sequences that enable the vector to replicate in one or more selected host cells. Typically in cloning vectors, these sequences enable the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast and viruses.
  • the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 ⁇ plasmid origin is suitable for yeast, and various viral origins (e.g. SV 40, polyoma, adeno virus) are useful for cloning vectors in mammalian cells.
  • the origin of replication component is not needed for mammalian expression vectors unless these are used in mammalian cells competent for high level DNA replication, such as COS cells.
  • Most expression vectors are shuttle vectors, i.e. they are capable of replication in at least one class of organisms but can be transfected into another organism for expression.
  • a vector is cloned in E. coli and then the same vector is transfected into yeast or mammalian cells even though it is not capable of replicating independently of the host cell chromosome.
  • DNA may also be replicated by insertion into the host genome.
  • the recovery of genomic DNA encoding the fusion protein of the invention is more complex than that of exogenously replicated vector because restriction enzyme digestion is required to excise the DNA.
  • DNA can be amplified by PCR and be directly transfected into the host cells without any replication component.
  • an expression and cloning vector may contain a selection gene also referred to as selectable marker.
  • This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium.
  • Typical selection genes encode proteins that confer resistance to antibiotics and other toxins, e.g. ampicillin, neomycin, methotrexate or tetracycline. complement auxotrophic deficiencies, or supply critical nutrients not available from complex media.
  • any marker gene can be used which facilitates the selection for transformants due to the phenotypic expression of the marker gene.
  • Suitable markers for yeast are, for example, those conferring resistance to antibiotics G418, hygromycin or bleomycin, or provide for prototrophy in an auxotrophic yeast mutant, for example the URA3, LEU2, LYS2, TRP1, or HIS3 gene.
  • E. coli genetic marker and an E. coli origin of replication are advantageously included. These can be obtained from E. coli plasmids, such as pBR322, Bluescript ® vector or a pUC plasmid, e.g. pUC18 or pUC19, which contain both E. coli replication origin and E. coli genetic marker conferring resistance to antibiotics, such as ampicillin.
  • Suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up vector nucleic acid, such as dihydrofolate reductase (DHFR, methotrexate resistance), thymidine kinase, or genes conferring resistance to G418 or hygromycin.
  • DHFR dihydrofolate reductase
  • thymidine kinase or genes conferring resistance to G418 or hygromycin.
  • the mammalian cell transformants are placed under selection pressure which only those transformants which have taken up and are expressing the marker are uniquely adapted to survive.
  • selection pressure can be imposed by culturing the transformants under conditions in which the pressure is progressively increased, thereby leading to amplification (at its chromosomal integration site) of both the selection gene and the linked DNA that encodes the fusion protein.
  • Amplification is the process by which genes in greater demand for the production of a protein critical for growth, together with closely associated genes which may encode a desired protein, are reiterated in tandem within the chromosomes of recombinant cells.
  • Increased quantities of desired protein are usually synthesised from thus amplified DNA.
  • Expression and cloning vectors usually contain a promoter that is recognised by the host organism and is operably linked to the fusion-protein encoding nucleic acid. Such a promoter may be inducible or constitutive.
  • the promoters are operably linked to DNA encoding the fusion protein by removing the promoter from the source DNA by restriction enzyme digestion and inserting the isolated promoter sequence into the vector. Both the native promoter sequence of one of the constituents of the fusion protein and many heterologous promoters may be used to direct amplification and/or expression of the DNA.
  • the term "operably linked” refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
  • a control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
  • Promoters suitable for use with prokaryotic hosts include, for example, the ⁇ -lactamase and lactose promoter systems, alkaline phosphatase, the tryptophan (tip) promoter system and hybrid promoters such as the tac promoter. Their nucleotide sequences have been published, thereby enabling the skilled worker operably to ligate them to DNA encoding the fusion protein using linkers or adaptors to supply any required restriction sites. Promoters for use in bacterial systems will also generally contain a Shine-Delgarno sequence operably linked to the DNA encoding the fusion protein.
  • Preferred expression vectors are bacterial expression vectors which comprise a promoter of a bacteriophage such as phagex or T7 which is capable of functioning in the bacteria.
  • the nucleic acid encoding the fusion protein may be transcribed from the vector by T7 RNA polymerase (Studier et al, Methods in Enzymol. 185; 60-89, 1990).
  • T7 RNA polymerase In the E. coli BL21(DE3) host strain, used in conjunction with pET vectors, the T7 RNA polymerase is produced from the ⁇ -lysogen DE3 in the host bacterium, and its expression is under the control of the IPTG inducible lac UV5 promoter.
  • This system has been employed successfully for over-production of many globular proteins, but in many other cases significant over-production cannot be achieved because of the toxicity of over-expression (Studier et ⁇ /. ,1990; George et al, J.
  • the polymerase gene may be introduced on a lambda phage by infection with an int- phage such as the CE6 phage which is commercially available (Novagen, Madison, USA).
  • other vectors include vectors containing the lambda PL promoter such as PLEX (Invitrogen, NL) , vectors containing the trc promoters such as pTrcHisXpressTm (Invitrogen) or pTrc99 (Pharmacia Biotech,
  • the fusion protein gene according to the invention may include a secretion sequence in order to facilitate secretion of the polypeptide from bacterial hosts, such that it will be produced as a soluble native peptide rather than in an inclusion body.
  • the peptide may be recovered from the bacterial periplasmic space, or the culture medium, as appropriate.
  • Suitable promoting sequences for use with yeast hosts may be regulated or constitutive and are preferably derived from a highly expressed yeast gene, especially a Saccharomyces cerevisiae gene.
  • the S. pombe nmt 1 gene or a promoter from the TATA binding protein (TBP) gene can be used.
  • TBP TATA binding protein
  • hybrid promoters comprising upstream activation sequences (UAS) of one yeast gene and downstream promoter elements including a functional TATA box of another yeast gene, for example a hybrid promoter including the UAS(s) of the yeast PH05 gene and downstream promoter elements including a functional TATA box of the yeast GAP gene (PH05-GAP hybrid promoter).
  • a suitable constitutive PHO5 promoter is e.g.
  • PH05 a shortened acid phosphatase PH05 promoter devoid of the upstream regulatory elements (UAS) such as the PH05 (-173) promoter element starting at nucleotide -173 and ending at nucleotide -9 of the PH05 gene.
  • UAS upstream regulatory elements
  • Fusion protein gene transcription from vectors in mammalian hosts may be controlled by promoters derived from the genomes of viruses such as polyoma virus, adenovirus, fowlpox virus, bovine papilloma virus, avian sarcoma virus, cytomegalo virus (CMV), a retrovirus and Simian Virus 40 (SV40), from heterologous mammalian promoters such as the actin promoter or a very strong promoter, e.g. a ribosomal protein promoter, and from the promoter normally associated with the gene encoding a component of the fusion protein, provided such promoters are compatible with the host cell systems.
  • viruses such as polyoma virus, adenovirus, fowlpox virus, bovine papilloma virus, avian sarcoma virus, cytomegalo virus (CMV), a retrovirus and Simian Virus 40 (SV40), from heterologous mammalian promoters such
  • Enhancers are relatively orientation and position independent. Many enhancer sequences are known from mammalian genes (e.g. elastase and globin). However, typically one will employ an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270) and the CMV early promoter enhancer. The enhancer may be spliced into the vector at a position 5' or 3' to the coding sequence, but is preferably located at a site 5' from the promoter.
  • a eukaryotic expression vector encoding the fusion protein may comprise a locus control region (LCR).
  • LCRs are capable of directing high-level integration site independent expression of transgenes integrated into host cell chromatin, which is of importance especially where the fusion protein gene is to be expressed in the context of a permanently-transfected eukaryotic cell line in which chromosomal integration of the vector has occurred, in vectors designed for gene therapy applications or in transgenic animals.
  • An expression vector includes any vector capable of expressing nucleic acids that are operatively linked with regulatory sequences, such as promoter regions, that are capable of expression of such DNAs.
  • an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector, that upon introduction into an appropriate host cell, results in expression of the cloned DNA.
  • Appropriate expression vectors are well known to those with ordinary skill in the art and include those that are replicable in eukaryotic and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.
  • DNAs encoding the fusion protein according to the invention may be inserted into a vector suitable for expression of cDNAs in mammalian cells, e.g. a CMV enhancer-based vector such as pEVRF (Matthias, et al. , (1989) NAR 17, 6418).
  • Transient expression usually involves the use of an expression vector that is able to replicate efficiently in a host cell, such that the host cell accumulates many copies of the expression vector, and, in turn, synthesises high levels of fusion protein.
  • transient expression systems are useful e.g. for identifying fusion protein mutants, to identify potential phosphorylation sites, or to characterise functional domains of the protein.
  • Plasmids employs conventional ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required. If desired, analysis to confirm correct sequences in the constructed plasmids is performed in a known fashion. Suitable methods for constructing expression vectors, preparing in vitro transcripts, introducing DNA into host cells, and performing analyses for assessing expression and function are known to those skilled in the art.
  • Gene presence, amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA, dot blotting (DNA or RNA analysis), or in situ hybridisation, using an appropriately labelled probe based on a sequence provided herein.
  • the invention moreover provides an expression vector comprising a fitst nucleic acid sequence encoding a polypeptide capable of forming a coiled coil structure operably linked to a promoter capable of expressing the first nucleic acid sequence in a host cell, and, linked to the nucleic acid sequence, a cloning site permitting the insertion of a second nucleic acid sequence such that it is capable of being expressed in fusion with the first nucleic acid sequence.
  • a vector is a useful vehicle for expressing nucleic acids encoding any desired polypeptide in the form of a fusion protein according to the invention.
  • a further embodiment of the invention provides host cells transformed or transfected with the vectors for the replication and expression of polynucleotides of the invention.
  • the cells will be chosen to be compatible with the vector and may for example be bacterial, yeast, insect or mammalian.
  • Such host cells such as prokaryote, yeast and higher eukaryote cells may be used for replicating DNA and producing the fusion protein.
  • Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, such as E. coli, e.g. E. coli K-12 strains, DH5a and HB101, or Bacilli.
  • Further hosts suitable for fusion protein encoding vectors include eukaryotic microbes such as filamentous fungi or yeast, e.g. Saccharomyces cerevisiae.
  • Higher eukaryotic cells include insect and vertebrate cells, particularly mammalian cells. In recent years propagation of vertebrate cells in culture (tissue culture) has become a routine procedure.
  • Examples of useful mammalian host cell lines are epithelial or fibroblastic cell lines such as Chinese hamster ovary (CHO) cells, NIH 3T3 cells, HeLa cells or 293T cells.
  • the host cells referred to in this disclosure comprise cells in in vitro culture as well as cells that are within a host animal.
  • DNA may be stably incorporated into cells or may be transiently expressed using methods known in the art.
  • Stably transfected mammalian cells may be prepared by transfecting cells with an expression vector having a selectable marker gene, and growing the transfected cells under conditions selective for cells expressing the marker gene. To prepare transient transfectants, mammalian cells are transfected with a reporter gene to monitor transfection efficiency.
  • the cells should be transfected with a sufficient amount of fusion protein-encoding nucleic acid to form the fusion protein.
  • the precise amounts of DNA encoding the fusion protein may be empirically determined and optimised for a particular cell and assay.
  • Host cells are transfected or, preferably, transformed with the above-captioned expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
  • Heterologous DNA may be introduced into host cells by any method known in the art, such as transfection with a vector encoding a heterologous DNA by the calcium phosphate coprecipitation technique or by electroporation. Numerous methods of transfection are known to the skilled worker in the field. Successful transfection is generally recognised when any indication of the operation of this vector occurs in the host cell. Transformation is achieved using standard techniques appropriate to the particular host cells used.
  • Transfected or transformed cells are cultured using media and culturing methods known in the art, preferably under conditions, whereby the fusion protein encoded by the DNA is expressed.
  • suitable media is known to those in the art, so that they can be readily prepared.
  • Suitable culturing media are also commercially available.
  • Microorganisms, and especially bacteria such as Escherichia coli are among the most successful vehicles for over-expression of both prokaryotic and eukaryotic proteins (for reviews see Hockney, 1994; Grisshammer & Tate, 1995).
  • host cells according to the invention includes microorganisms transformed with vectors encoding fusion proteins according to the invention.
  • expression systems employed to express many prokaryotic proteins, including membrane proteins, some cytoplasmic proteins (Dong et al. ,
  • eukaryotic proteins in microorganisms can be equally problematical. Over expression of such proteins can also be toxic to the cell. Nonetheless, bacterial expression systems are used in industry and have been used to express a wide variety of proteins, including chymosin, insulin, interferons, insulin-like growth factors, antibodies including humanised antibodies, or fragments thereof.
  • the invention provides a method for improving an expression system comprising the steps of:
  • the fusion polypeptide is a fusion protein according to the invention, comprising a coiled coil region and a further region encoding a desired protein product.
  • desired proteins include bovine oxoglutarate-malate carrier, ADP/ATP translocase, rat uncoupling proteins UCP1 and UCP2, Escherichia coli unc I , E. coli F-ATPase subunit a, bovine F-ATPase subunit epsilon and human immuno-defficiency virus TAT protein.
  • Preferred bacterial hosts which may be used in the above method include B strains of E. coli such as BL21 or a K strain such as JM109. These strains are widely available in the art from academic and/or commercial sources. The B strains are deficient in the Ion protease and other strains with this genotype may also be used. Preferably the strain should not be defective in recombination genes.
  • the strain is BL21(DE3), as disclosed in Studier et al. (1990) .
  • Bacteria obtainable by the above selection method, optionally cured of the vector, may also be used as host cells in the present invention.
  • Particular bacteria include E. coli C43 (DE3) (deposited at the European Collection of Cell Cultures (ECCC) , Salisbury, Wiltshire, UK on 4th July 1996 asB96070445); E. coli C0214(DE3) (deposited at the National Collections of Industrial and Marine Bacteria on 25th June 1997 as NCIMB 40884); E. coli DK8(DE3)S (deposited at the National Collections of Industrial and Marine Bacteria on 25th June 1997 as NCIMB 40885); or E. coli C41(DE3) (deposited at the ECCC on 4th
  • Such bacteria when cured, provide a host for the expression of fusion proteins of the invention and are especially suitable for the expression of fusion proteins whose expression is toxic to bacteria.
  • Cultivation of the host cells will take place in the presence of selection pressure, usually in the presence of an antibiotic which is metabolised by the selectable marker gene of the vector.
  • concentration of antibiotic used will depend upon the exact nature of the resistance gene and the concentration at which untransformed cells are killed by the antibiotic. In the case of ampicillin, somewhere between 20 and 200 ⁇ g per ml of culture will usually be sufficient, although this may be determined empirically if need be by those of skill in the art. In general, suitable concentrations of antibiotics may be determined by reference to standard laboratory reference books (e.g. Sambrook et al, 1989).
  • the hosts initially will be cultivated under conditions where little or no expression of the target gene occurs so that log phase growth of the cells are achieved.
  • E.coli this will typically mean that the cells are grown to a density of around 10 cells per ml, for example in the range of from 10 to 10 per ml.
  • the cell density may be measured using optical density measurements.
  • the cells may be grown for a suitable period of time, e.g. from 1 to 6, e.g. from 3 to 4 hours at 37°C.
  • the cells may also be cultured at a lower or higher temperature. This may be useful where for example the expression of the target polypeptide is linked to a temperature-sensitive gene. In such a situation the cells would first be grown at the non-permissive temperature, i.e. the temperature where expression of the target gene does not occur. Following the culturing of the cells under selection pressure the culture will be induced to express the target gene.
  • a number of inducible promoters operable in bacteria are available. Some promoters, such as the trpE promoter, are inducible by the presence or absence of metabolites or catabolites in the media (namely tryptophan in the case of the trpE promoter). Other promoters include the tac promoter or the lambda P R promoter.
  • a preferred promoter is however a bacteriophage promoter which requires a bacteriophage polymerase for expression.
  • a preferred promoter is the T7 promoter which may be used in conjunction with a cell in which the T7 polymerase gene has been cloned and placed under the control of a separate inducible promoter.
  • the T7 polymerase is selective for its promoter binding site and is thus particularly useful since in the absence of T7 polymerase little expression of the target gene will occur.
  • the gene encoding the polymerase is introduced into the cell in a lambda phage and is situated in the phage genome within the int gene so that the phage needs a helper phage for integration or excision from the genome.
  • the polymerase gene is linked to the UV5 promoter which is inducible by isopropyl- ⁇ -D-thiogalactopyranoside (IPTG) so that addition of IPTG to the culture induces the production of T7 polymerase.
  • IPTG isopropyl- ⁇ -D-thiogalactopyranoside
  • the gene may be introduced on a lambda phage by infection with an inf phage such the CE6 phage which is commercially available (Novagen, Madison, USA).
  • the culture should be maintained for a suitable period of time such that cell death starts to occur, and cells in the culture start to loose the vector encoding the target polypeptide.
  • the cells should be maintained in liquid culture until no more than 50% and preferably no more than 10%, e.g. 1 % or 0.1 % of cells retain the vector. This may be determined by plating duplicate aliquots of the culture on solid medium with and without the selection pressure and determining the ratio between the number of colonies which grow under selective and non-selective conditions.
  • the fresh medium is desirably a solid medium, typically agar which contains the necessary nutrients for cell growth. Survivors are examined for the presence of the target gene. We have surprisingly found that some of the colonies recovered from this medium contain cells which are resistant to the toxic effects of the target gene. This is in contrast to normal practice in the art which has regarded the "spent" culture as a waste product following recovery of the target polypeptide.
  • Host cells of the invention may be cultured under conditions in which expression of the fusion protein occurs.
  • the fusion protein may be recovered by any suitable means, for example affinity chromatography or HPLC. Where small fusion proteins are involved HPLC is particularly suitable.
  • the fusion protein may be cleaved, e.g. using an appropriate protease, to provide the polypeptide sequence of interest and this sequence may be recovered from the resulting mixture of first and second regions of the fusion protein.
  • the fusion protein may find application as such, for example as an immunogen where the coiled-coils form aggregates. This avoids the necesssity for preparing immunogenic material form small proteins and peptides by coupling them by separate chemical reaction to a carrier protein such as key-hole limpet hemocyanin (KLH).
  • KLH key-hole limpet hemocyanin
  • Fusion proteins according to the invention may be used directly as immunogens, without the use of further adjuvants, to generate antisera and monoclonal antibodies.
  • antibodies specifically recognising and binding the fusion proteins according to the invention. More preferably, however, the antibodies are specific for the second region of the fusion proteins, that is the polypeptide which is fused to the gene product of the invention in order to achieve expression thereof.
  • the second region of the fusion protein is recognised by the antibodies when in its natural context.
  • the second region is an isolated peptide or domain from a larger protein, that peptide or domain is recognised by the antibodies of the invention in the context of the whole of the larger protein.
  • the invention moreover provides a method for preparing an immunoglobulin, comprising the steps of:
  • the antibodies may be isolated in the form of a crude preparation, i.e. an antiserum, by affinity chromatography against the fusion protein or the protein from which one region of the fusion protein is derived.
  • this region is the second region.
  • the antibody recognises both the coiled coil and the fused protein, it may be isolated using a different fusion between the fused protein and a different colied coil structure.
  • the animals used for antibody production may be any animals normally employed for the purpose, particularly mammals. Especially indicated are mice, rats, guinea pigs and rabbits.
  • antibodies directed to the fusion protein and antibodies raised against the fusion protein which are specific for the one region thereof are referred to as "anti-fusion protein” antibodies.
  • Antibodies according to the invention may be whole antibodies of natural classes, such as IgE and IgM antibodies, but are preferably IgG antibodies. Moreover, the invention includes antibody fragments, such as Fab, F(ab')2, Fv and ScFv. Small fragments, such as
  • Fv and ScFv possess advantageous properties for diagnostic and therapeutic applications on account of their small size and consequent superior tissue distribution.
  • the antibodies according to the invention are especially indicated for diagnostic and therapeutic applications. Accordingly, they may be altered antibodies comprising an effector protein such as a toxin or a label. Especially preferred are labels which allow the imaging of the distribution of the antibody in a tumour in vivo. Such labels may be radioactive labels or radioopaque labels, such as metal particles, which are readily visualisable within the body of a patient. Moreover, the may be fluorescent labels or other labels which are visualisable on tissue samples removed from patients.
  • chimeric antibodies may be constructed in order to decrease the immunogenicity thereof in diagnostic or therapeutic applications.
  • immunogenicity may be minimised by humanising the antibodies by CDR grafting [see European Patent Application 0 239 400 (Winter)] and, optionally, framework modification.
  • human antibodies may be synthesised using phage display selection techniques.
  • Antibodies according to the invention may be obtained from animal serum, or. in the case of monoclonal antibodies or fragments thereof, produced in cell culture. Recombinant DNA technology may be used to produce the antibodies according to established procedure, in bacterial or preferably mammalian cell culture. The selected cell culture system preferably secretes the antibody product.
  • the present invention includes a process for the production of an antibody according to the invention comprising culturing a host, e.g. E. coli or a mammalian cell, which has been transformed with a hybrid vector comprising an expression cassette comprising a promoter operably linked to a first DNA sequence encoding a signal peptide linked in the proper reading frame to a second DNA sequence encoding said protein, and isolating said protein.
  • a host e.g. E. coli or a mammalian cell
  • a hybrid vector comprising an expression cassette comprising a promoter operably linked to a first DNA sequence encoding a signal peptide linked in the proper reading frame to a second DNA sequence encoding said protein, and isolating said protein.
  • Multiplication of hybridoma cells or mammalian host cells in vitro is carried out in suitable culture media, which are the customary standard culture media, for example Dulbecco's Modified Eagle Medium (DMEM) or RPMI 1640 medium,
  • feeder cells such as normal mouse peritoneal exudate cells, spleen cells, bone marrow macrophages, 2-aminoethanol, insulin, transferrin, low density lipoprotein, oleic acid, or the like.
  • Multiplication of host cells which are bacterial cells or yeast cells is likewise carried out in suitable culture media known in the art, for example for bacteria in medium LB, NZCYM, NZYM, NZM, Terrific Broth, SOB, SOC, 2 x YT, or M9
  • Minimal Medium and for yeast in medium YPD, YEPD, Minimal Medium, or Complete Minimal Dropout Medium.
  • In vitro production provides relatively pure antibody preparations and allows scale-up to give large amounts of the desired antibodies.
  • Techniques for bacterial cell, yeast or mammalian cell cultivation are known in the art and include homogeneous suspension culture, e.g. in an airlift reactor or in a continuous stirrer reactor, or immobilised or entrapped cell culture, e.g. in hollow fibres, microcapsules, on agarose microbeads or ceramic cartridges.
  • the desired antibodies can also be obtained by multiplying mammalian cells in vivo.
  • hybridoma cells producing the desired antibodies are injected into histocompatible mammals to cause growth of antibody-producing tumours.
  • the animals are primed with a hydrocarbon, especially mineral oils such as pristane (tetramethyl-pentadecane), prior to the injection.
  • pristane tetramethyl-pentadecane
  • hybridoma cells obtained by fusion of suitable myeloma cells with antibody-producing spleen cells from Balb/c mice, or transfected cells derived from hybridoma cell line Sp2/0 that produce the desired antibodies are injected intraperitoneally into Balb/c mice optionally pre-treated with pristane, and, after one to two weeks, ascitic fluid is taken from the animals.
  • the cell culture supernatants are screened for the desired antibodies, preferentially by immunofluorescent staining of cells expressing the fusion protein, by immunoblotting, by an enzyme immunoassay, e.g. a sandwich assay or a dot-assay, or a radio immunoassay.
  • the immunoglobulins in the culture supernatants or in the ascitic fluid may be concentrated, e.g. by precipitation with ammonium sulphate, dialysis against hygroscopic material such as polyethylene glycol, filtration through selective membranes, or the like.
  • the antibodies are purified by the customary chromatography methods, for example gel filtration, ion-exchange chromatography, chromatography over DEAE-cellulose and/or immuno-affinity chromatography, e.g. affinity chromatography with the relevant (part of the) fusion protein or with Protein-A.
  • the invention further concerns hybridoma cells secreting the monoclonal antibodies of the invention.
  • the preferred hybridoma cells of the invention are genetically stable, secrete monoclonal antibodies of the invention of the desired specificity and can be activated from deep-frozen cultures by thawing and recloning.
  • the invention also concerns a process for the preparation of a hybridoma cell line secreting monoclonal antibodies directed to the fusion proteins characterised in that a suitable mammal, for example a Balb/c mouse, is immunised with purified fusion protein, or with cells bearing the fusion protein, antibody-producing cells of the immunised mammal are fused with cells of a suitable myeloma cell line, the hybrid cells obtained in the fusion are cloned, and cell clones secreting the desired antibodies are selected.
  • a suitable mammal for example a Balb/c mouse
  • spleen cells of Balb/c mice immunised with the fusion protein are fused with cells of the myeloma cell line PAI or the myeloma cell line Sp2/0-Agl4, the obtained hybrid cells are screened for secretion of the desired antibodies, and positive hybridoma cells are cloned.
  • a fusion promoter preferably polyethylene glycol.
  • the myeloma cells are fused with a three- to twentyfold excess of spleen cells from the immunised mice in a solution containing about 30 % to about 50 % polyethylene glycol of a molecular weight around 4000.
  • the cells are expanded in suitable culture media as described hereinbefore, supplemented with a selection medium, for example HAT medium, at regular intervals in order to prevent normal myeloma cells from overgrowing the desired hybridoma cells.
  • the invention also concerns recombinant nucleic acids comprising an insert coding for a heavy chain variable domain and/or for a light chain variable domain of antibodies directed to the fusion proteins of the invention.
  • DNAs comprise coding single stranded DNAs, double stranded DNAs consisting of said coding DNAs and of complementary DNAs thereto, or these complementary (single stranded) DNAs themselves.
  • DNA encoding a heavy chain variable domain and/or for a light chain variable domain of antibodies directed the fusion proteins can be enzymatically or chemically synthesised DNA having the authentic DNA sequence coding for a heavy chain variable domain and/or for the light chain variable domain, or a mutant thereof.
  • a mutant of the authentic DNA is a DNA encoding a heavy chain variable domain and/or a light chain variable domain of the above-mentioned antibodies in which one or more amino acids are deleted or exchanged with one or more other amino acids.
  • said modification(s) are outside the CDRs of the heavy chain variable domain and/or of the light chain variable domain of the antibody.
  • Such a mutant DNA is also intended to be a silent mutant wherein one or more nucleotides are replaced by other nucleotides with the new codons coding for the same amino acid(s).
  • Such a mutant sequence is also a degenerated sequence.
  • Degenerated sequences are degenerated within the meaning of the genetic code in that an unlimited number of nucleotides are replaced by other nucleotides without resulting in a change of the amino acid sequence originally encoded.
  • Such degenerated sequences may be useful due to their different restriction sites and/or frequency of particular codons which are preferred by the specific host, particularly E. coli, to obtain an optimal expression of the heavy chain murine variable domain and/or a light chain murine variable domain.
  • mutant is intended to include a DNA mutant obtained by in vitro mutagenesis of the authentic DNA according to methods known in the art.
  • the recombinant DNA inserts coding for heavy and light chain variable domains are fused with the corresponding DNAs coding for heavy and light chain constant domains, then transferred into appropriate host cells, for example after incorporation into hybrid vectors.
  • the invention therefore also concerns recombinant DNAs comprising an insert coding for a heavy chain murine variable domain of an antibody directed against a fusion protein according to the invention fused to a human ⁇ constant domain, for example ⁇ l, ⁇ 2, ⁇ 3 or ⁇ 4, preferably ⁇ l or ⁇ 4.
  • the invention concerns recombinant DNAs comprising an insert coding for a light chain murine variable domain of an antibody directed to the fusion protein fused to a human constant domain K or ⁇ , preferably K.
  • the invention pertains to recombinant DNAs coding for a recombinant DNA wherein the heavy chain variable domain and the light chain variable domain are linked by way of a DNA insert coding for a spacer group, optionally comprising a signal sequence facilitating the processing of the antibody in the host cell and/or a DNA coding for a peptide facilitating the purification of the antibody and/ or a DNA coding for a cleavage site and/or a DNA coding for a peptide spacer and/or a DNA coding for an effector molecule.
  • a DNA insert coding for a spacer group optionally comprising a signal sequence facilitating the processing of the antibody in the host cell and/or a DNA coding for a peptide facilitating the purification of the antibody and/ or a DNA coding for a cleavage site and/or a DNA coding for a peptide spacer and/or a DNA coding for an effector molecule.
  • the DNA coding for an effector molecule is intended to be a DNA coding for the effector molecules useful in diagnostic or therapeutic applications.
  • effector molecules which are toxins or enzymes, especially enzymes capable of catalysing the activation of prodrugs, are particularly indicated.
  • the DNA encoding such an effector molecule has the sequence of a naturally occurring enzyme or toxin encoding DNA, or a mutant thereof, and can be prepared by methods well known in the art.
  • Antibodies and antibody fragments according to the invention are useful in diagnosis and therapy. Accordingly, the invention provides a composition for therapy or diagnosis comprising an antibody according to the invention.
  • the antibody is preferably provided together with means for detecting the antibody, which may be enzymatic, fluorescent, radioisotopic or other means.
  • the antibody and the detection means may be provided for simultaneous, simultaneous separate or sequential use, in a diagnostic kit intended for diagnosis.
  • Fusion proteins according to the invention possess an extremely small fusion partner.
  • One advantage thereof is that the fusion proteins may be employed directly in an NMR experiment without the fusion partner interfering in the spectrum received.
  • NMR analysis may be performed according to techniques and methododlogy which are known in the art, for example as described in K. W ⁇ rtrich, "NMR of Proteins and Nucleic Acids", Wiley, New York, 1986, incorporated herein by reference.
  • E. coli C41(DE3) One freshly transformed colony of the expression host, E. coli C41(DE3), is inocculated into 500 ml of 2xTY medium.
  • the expression of the fusion protein is induced by addition of IPTG (0.7 mM final concentration).
  • IPTG 0.7 mM final concentration
  • the temperature of growth is reduced to 25 °C, and the culture is left for 18 hours.
  • the cells are harvested by centrifugation, resuspended in TEP buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, and 0.001 % phenylmethyl sulphonyl fluoride) and broken by being passed twice through a French pressure cell. The broken cells are centrifuged (60 minutes, 100,000 x g).
  • the over-expressed protein is soluble in the bacterial cytosol
  • the supernatant from the centrifuged broken bacterial cells is applied to a column of S-Sepharose equilibrated in TEP buffer. Proteins bound to the colomn are eluted with a linear gradient of sodium chloride (0-1M). Most of the fusion proteins elute from the column at a salt concentration of about 0.5 M sodium chloride, except for the If-ADPl fusion protein, which eluted at about 0.9 M sodium chloride. The purity of the proteins is examined by SDS-PAGE.
  • Ni-NTA resin supplied by Quiagen Inc, Chatsworth, CA91311, U. S. A. NTA is nitrilo-triacetic acid).
  • C41(DE3) is redissolved in PBS containing 6M guanidinium hydrochloride and 0.33 M sodium chloride. Insoluble material is removed by centrifugation (40,000 g, 10 min), and the fusion protein is purified from the supernatant either by reverse-phase HPLC or by Ni- NTA column chromatography, as described below.
  • Ni-NTA colum chromatography The sample of If-epsilon dissolved in 6M-guanidine hydrochloride is applied to a column of n Ni-NTA resin (2 ml bed volume). The column is equilibrated in PBS containing 0.33 M sodium chloride. It is washed first with PBS containing 5 mM imidazole (20 ml), and then with PBS containing 50 mM imidazole (20 ml) to elute the If-epsilon. The protein is a detected in the effluent by monitoring the absorbance at 225 nm. The purity of the protein is confirmed by SDS-PAGE.
  • If-UCP270 This protein (which contains a histidineg tag at its C-terminal end) is expressed in E. coli C41(DE3), where it also forms inclusion bodies in the bacterial cytoplasm.
  • the culture is harvested by centrifugation and the cells are resuspended in PBS buffer containing 0.3 M sodium chloride. Cells are passed twice through a French press, and unbroken cells are eliminated by low speed centrifugation (2,000 x g, 10 minutes). Inclusion bodies are collected by centrifugation (10,000g, 10 minutes). The inclusion body pellet is resuspended in PBS buffer to a protein concentration of 2 mg/ml.
  • buffer A which contains 0.1 M sodium phosphate, 0.01 Tris-HCl, 8.0 and 6M guanidine hydrochloride. Any remaining insoluble material is removed by centrifugation (10.000 x g, 10 minutes).
  • the supernatant is mixed with 2 ml of a slurry of Ni-NTA resin that has been equilibrated in the same buffer. The slurry is stirred at room temperature for 45 minutes, then poured into a 5 ml chromatography column. The column is washed successively with 10 volumes of buffer A, pH 8.0, and 5 volumes of buffer B (8 M urea.
  • the fusion protein is eluted by washing the column with 4 ml of buffer C, containing 8M urea, 0.1 M sodium phosphate, 0.01 M Tris, pH 4.5.
  • the detergent lauryl-dimethylamine oxide (LDAO; final concentration 1 %) is added to the eluted fractions, and urea is removed by three successive dialysis steps (3 hours each) with the following buffers: first, buffer A, pH 8.0, containing 0.15 % LDAO and 4M urea; second,buffer A, pH 8.0, containing 0.15 % LDAO and 0.5M urea; third, buffer A, pH 8.0 containing 0.15 % LDAO.
  • Fractions containing the fusion protein are pooled and incubated 45 minutes at 4°C with 2 ml of Ni-NTA resin pre-equilibrated with a PBS buffer containing 0.3M sodium chloride. The mixture is then poured into a 10 ml chromatography column and washed with PBS buffer containing 5 mM imidazole (20 ml). Fusion proteins without an additional C-terminal His-tag are eluted with buffer containing 50 mM imidazole and those with an additional C-terminal His-tag with buffer containing 500 mM imidazole. The fusion proteins are dialysed against PBS buffer and concentrated by ultrafiltration with an Amicon column 3.
  • the pMW T7 expression vector (Studier et al. , 1990; Way et al , 1990) was adapted to express fusion proteins comprising a coiled coil fusion partner consisting of amino acids 44 to 84 of IF,.
  • a coiled coil fusion partner consisting of amino acids 44 to 84 of IF
  • the amino acid sequence shown in SEQ. ID. No. 1 which consist of amino acids 44 to 84 of IF, preceded by an initiating ATG (Met), is linked downstream of the T7 promoter in pMW by ligating it at the Nde 1 restriction site therein.
  • the cleavable linker G S P K L Downstream of the IF, sequence, the cleavable linker G S P K L is inserted, which provides BamHl and Hindlll restriction endonuclease sites. This sequence is part of the reverse primer used for vector construction and corresponds to the BamHI and Hindlll sites in the vector.
  • Figure 1, lane 1 shows the expression of the fusion partner plus cleavable linker alone.
  • the expression vector is transformed into E. coli C41(DE3) cells (see UK patent application 9614700.4; also Miroux and Walker, 1996).
  • One transformant colony is inoculated into 500ml 2x TY medium in the presence of ampicillin (100 ⁇ g/ml) and grown at 37°C until the culture has reached an ODgoo of 0.6.
  • fusion partner expression is induced by the addition to the culture of 0.7 mM IPTG.
  • Cells are harvested 16 hours after induction, and lysed in SDS-PAGE solubilisation buffer. The equivalent of 7.5 ⁇ l of culture is mixed with an equal volume of SDS-PAGE buffer and loaded, without further purification, onto a 12-22% SDS-PAGE gel. The gel is then stained with coomassie blue 83 dye.
  • the expressed polypeptide is visible as a major constituent of the total cellular protein in the bacteria.
  • the vector described above is further modified by the addition of a MCS and a His tag.
  • the His tag facilitates isolation of the fusion protein on a nickel column, although it is not strictly necessary because the IF, 44-84 sequence itself contains
  • Fusion polypeptides are expressed by cloning nucleic acid sequences encoding amino acids 1 to 39 and 118 to 155 of subunit a of E. coli F,F 0 ATP Synthase, and amino acids 1 to 13 and 55 to 75 of subunit I of E. coli F,F 0 ATP Synthase directly onto the GSPKL extension of the 44-84 sequence of IF, in the expression vector described in Example 1. The results of the experiment are shown in Figure 1, lanes 2 to 5.
  • the expression vectors are transformed into E. coli C41(DE3).
  • One transformant colony is inoculated into 500ml 2x TY medium in the presence of ampicillin (100 ⁇ g/ml) and grown at 37°C until the culture has reached an OD 600 of 0.6.
  • fusion partner expression is induced by the addition to the culture of 0.7 mM IPTG.
  • Cells are cultured at the reduced temperature of 25°C and harvested by centrifugation 18 hours after induction, or 3 hours after induction in the case of the IF, (44-84)-a(l-39) fusion.
  • the equivalent of 7.5 ⁇ l of culture is then loaded, without further purification, onto a 12-22% SDS-PAGE gel. The gel is then stained with coomassie blue 83 dye.
  • the expressed polypeptides are visible as major constituents of the total cellular protein in the bacteria.
  • Table 1 shows the results of expression experiments conducted with a number of fusion proteins. In two cases, involving fusions with a portion of the rat mitochondrial uncoupling protein, His-tags were used to further facilitate isolation on nickel columns. Two fusions with the epsilon subunit of bovine F,F 0 ATP synthase were made using alternative cleavable sequences, those for Factor Xa and Thrombin.
  • E. coli C41(DE3) cells were transformed as above and the proteins isolated from the cytosol, other in soluble form or as inclusion bodies as indicated.
  • the inclusion bodies are solubilised either in 6M-guanidium chloride or in 8M-urea and after solubilisation are centrifuged to eliminate membranes and insoluble material.
  • the supernatant conatining the solubilized protein is injected on to a reverse phase HPLC column (C8 Aquapore RP-300, 7 ⁇ m particles, 300 A pore size; 10 cm x 2.1 mm internal diameter) that has been equilibrated in 0.1 % trifluoroacetic acid and eluted with a linear gradient of acetonitrile.
  • the eluted peptides are detected by monitoring the absorbance of the efluent at 220 nm, and they are analyzed by SDS-PAGE.
  • the mass of the fusion protein was calculated by theoretical means and determined experimentally by electro-spray ionisation mass spectrometry with a Perkin- Elmer Sciex API III+ triple quadrupole mass spectrometer.
  • the purified protein or peptide sample was dissolved in water or in 0.1 % trifluoroacetic acid, and introduced into the inlet stream being sprayed into the instrument. This stream consisted of 50% aqueous acetonitrile. Spectra were recorded in the mass range 10-2,400 (see Methods in Molecular Biology, Volume 61: "Protein and Peptide Analysis by Mass Spectrometry”: Edited by J. R. Chapman, Humana Press, 1996; M. Mann and M. Wilm (1995) Trends Biochem Sci. 20, 219-224). The correlation between calculated and determined values is striking, indicating that the polypeptide is entirely undegraded during the synthesis procedure.
  • Inhibitor bovine inhibitor of the F,F 0 -ATP synthase
  • Eca subunit a of the E. coli F,F 0 -ATP synthase
  • uncl subunit I of the E.
  • coli synthase coli synthase
  • OGCP bovine mitochondrial oxoglutarate carrier
  • AAC bovine adenine nucleotide translocator
  • UCPI rat mitochondrial Uncoupling protein 1
  • UCP2 rat mitochondrial Uncoupling protein 2
  • ADPI peptide from HIV-TAT protein
  • epsilon subunit of the bovine F,F 0 -ATP synthase
  • e subunit of the bovine F,F 0 -ATP synthase
  • IB inclusion Bodies
  • m membrane protein
  • g globular protein
  • aa amino-acid
  • LDAO lauryl dimethylamine oxide.
  • Nickel columns Figure 5 shows the purification of fusion proteins according to the invention by nickel column and reverse phase HPLC methods. 1/ shows the purification of proteins from inclusion bodies: If-al is expressed as inclusion bodies and solubilised using 6M
  • K-UCP270 fusion protein is solubilised in the presence of urea and purified on a nickel column in the presence of LDAO detergent (see General Procedures for details).
  • Thse fusions are soluble in bacterial cytoplasm and are purified by anion exchange chromatography on S-Sepharose (see General Procedures) followed by affinity chromatography on a nickel column. All protein samples are analysed by SDS-PAGE after purification. The gels are stained with coomassie blue dye 83.
  • Nickel columns therefore provide convenient and efficient means by which fusion protyeins according to the invention may be purified.
  • FIGS 3 and 4 illustrate the purification of fusion proteins according to the invention by reverse phase HPLC (see General Procedures; also table 1).
  • Polypeptides to be isolated by reverse phase HPLC are isolated from bacterial host cells in the form of inclusion bodies and approximately 150 ⁇ g of material dissolved in 6M guanidinium hydrochloride in 0.1 M Tris.HCl, pH 8.0. The sample was injected into an Aquapore RP300 column using a HP 1090 Liquid Chromatograph.
  • a fusion protein comprising amino acids 44 to 84 of IF, fused, via the linker GSPKL, to residues 1 to 39 of the a subunit of E. coli F,F 0 ATP synthase is used directly for challenge of rabbits in order to generate anti-F,F 0 ATP synthase antibodies.
  • Antibodies capable of selective binding to the chosen polypeptide are obtained by this method.
  • a fusion protein is subjected to NMR analysis according to conventional techniques (K. W ⁇ rtrich, "NMR of Proteins and Nucleic Acids", Wiley, New York, 1986), but without separating the fusion partner from the polypetide to be analysed.
  • T7 lysozyme inhibits transcription by T7 RNA polymerase. Cell 49, 221-227.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention porte sur une protéine de fusion comprenant: a) une première région capable de former une structure bispiralée; et b) une seconde région non naturellement associée à la première et comprenant une séquence polypeptidique. Cette protèine de fusion peut être utilisée dans la production de très petits polypeptides dans des cellules hôtes transformées.
PCT/GB1998/002040 1997-07-11 1998-07-10 Proteines de fusion comprenant des structures bispiralees WO1999002707A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP98933782A EP1012310A1 (fr) 1997-07-11 1998-07-10 Proteines de fusion comprenant des structures bispiralees
CA002290716A CA2290716A1 (fr) 1997-07-11 1998-07-10 Proteines de fusion comprenant des structures bispiralees
AU83481/98A AU740755B2 (en) 1997-07-11 1998-07-10 Fusion proteins comprising coiled-coil structures
JP2000502201A JP2001509390A (ja) 1997-07-11 1998-07-10 コイルドコイル構造を含む融合タンパク質

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9714681.5A GB9714681D0 (en) 1997-07-11 1997-07-11 Recombinant production of proteins
GB9714681.5 1997-07-11

Publications (1)

Publication Number Publication Date
WO1999002707A1 true WO1999002707A1 (fr) 1999-01-21

Family

ID=10815748

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/002040 WO1999002707A1 (fr) 1997-07-11 1998-07-10 Proteines de fusion comprenant des structures bispiralees

Country Status (6)

Country Link
EP (1) EP1012310A1 (fr)
JP (1) JP2001509390A (fr)
AU (1) AU740755B2 (fr)
CA (1) CA2290716A1 (fr)
GB (1) GB9714681D0 (fr)
WO (1) WO1999002707A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017017028A1 (fr) * 2015-07-24 2017-02-02 Evoxx Technologies Gmbh Agrégats protéiques catalytiquement actifs et leurs méthodes de production
WO2019070711A1 (fr) * 2017-10-03 2019-04-11 The Regents Of The University Of California Rapporteurs, fondés sur la séparation des phases, d'interactions protéine-protéine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012988A1 (fr) * 1995-10-06 1997-04-10 Pence Procede et compositions faisant intervenir un heterodimere bispirale pour la detection et la purification de proteines exprimees

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012988A1 (fr) * 1995-10-06 1997-04-10 Pence Procede et compositions faisant intervenir un heterodimere bispirale pour la detection et la purification de proteines exprimees

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
TRIPET B. ET AL.: "Engineering a de novo-designed coiled - coil heterodimerization domain off the rapid detection, purification and characterization of recombinantly expressed peptides and proteins.", PROTEIN ENGINEERING, vol. 9, no. 11, 1996, pages 1029 - 1042, XP002085106 *
VAN RAAIJ M. J. ET AL.: "The ATPase inhibitor protein from bovine heart mitochondria: The minimal inhibitory sequence.", BIOCHEMISTRY, vol. 35, 1996, pages 15618 - 15625, XP002085104 *
WOLBER V. ET AL.: "A universal expression-purification system based on the coiled-coil interaction of myosin heavy chain.", BIO/TECHNOLOGY, vol. 10, 1992, pages 900 - 904, XP002085105 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017017028A1 (fr) * 2015-07-24 2017-02-02 Evoxx Technologies Gmbh Agrégats protéiques catalytiquement actifs et leurs méthodes de production
CN109477113A (zh) * 2015-07-24 2019-03-15 爱沃克斯技术有限责任公司 催化活性蛋白质聚集体及其制备方法
US11059865B2 (en) 2015-07-24 2021-07-13 Evoxx Technologies Gmbh Catalytically active protein aggregates and methods for producing the same
WO2019070711A1 (fr) * 2017-10-03 2019-04-11 The Regents Of The University Of California Rapporteurs, fondés sur la séparation des phases, d'interactions protéine-protéine
US11448654B2 (en) 2017-10-03 2022-09-20 The Regents Of The University Of California Protein-protein interaction assessed by detecting localized coiled coil subunits

Also Published As

Publication number Publication date
AU740755B2 (en) 2001-11-15
AU8348198A (en) 1999-02-08
JP2001509390A (ja) 2001-07-24
EP1012310A1 (fr) 2000-06-28
GB9714681D0 (en) 1997-09-17
CA2290716A1 (fr) 1999-01-21

Similar Documents

Publication Publication Date Title
Kane et al. Protein splicing converts the yeast TFP1 gene product to the 69-kdDSubunit of the vacuolar H+-adenosine triphosphatase
Bayliss et al. Interaction between NTF2 and xFxFG-containing nucleoporins is required to mediate nuclear import of RanGDP
JP2882775B2 (ja) ヒトーグリア由来神経突起因子
Wu et al. Structure and evolution of a multidomain multiphosphoryl transfer protein: nucleotide sequence of the fruB (HI) gene in Rhodobacter capsulatus and comparisons with homologous genes from other organisms
de la Brousse et al. Molecular and genetic characterization of GABP beta.
CA2190254A1 (fr) Facteurs associes au recepteur du facteur de necrose tumorale
JPH01501283A (ja) 新規な型のコロニー刺激因子―１
US6498020B1 (en) Fusion proteins comprising coiled-coil structures derived of bovine IF1 ATPase inhibitor protein
JP2008509682A (ja) Ｙｅｂｆを利用するタンパク質の製造方法
CA2376062A1 (fr) Proteines hybrides comprenant un fragment d'un polypeptide chaperon
US20030096956A1 (en) Process for producing kiss-1 peptide
EP1183363A2 (fr) Methodes de regulation de la conformation de proteines au moyen de chaperons moleculaires
AU740755B2 (en) Fusion proteins comprising coiled-coil structures
AU609128B2 (en) Leukaemia-inhibitory factor
AU710551B2 (en) Nucleic acid encoding a nervous tissue sodium channel
WO2006120019A2 (fr) Utilisation de nouveau codage genique pour nouvel element de la famille mcm2-8 dans les compositions pharmaceutiques
JPH10500311A (ja) 核タンパク質と相互作用する因子
JPH08504602A (ja) Ｔｉａ−１結合タンパク質及びそれをコードする分離された相補的ｄｎａ
FI97549C (fi) Menetelmä vierasproteiinien valmistamiseksi Streptomycessoluissa
WO2024178215A2 (fr) Biocapteur chimérique pour la détection de 2'3'-gmp-amp cyclique (cgamp) et ses procédés d'utilisation
JP2839837B2 (ja) 顆粒球コロニー刺激因子受容体のリガンド結合領域蛋白質をコードしているｄｎａ
JPS61181380A (ja) 新規ｄｎａおよびその用途
WO1998035037A1 (fr) Proteines a phosphorylation de tyrosine et associees a un sillon de clivage (pstpip)
WO1998035037A9 (fr) Proteines a phosphorylation de tyrosine et associees a un sillon de clivage (pstpip)
Chang Characterization of the protein import pathway in pea chloroplast

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 83481/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2290716

Country of ref document: CA

Ref country code: CA

Ref document number: 2290716

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998933782

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998933782

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 83481/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998933782

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载